| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/13/2010 | EP2142645A2 Use of an mmp28 inhibitor for increasing myelination |
| 01/13/2010 | EP2142570A2 Anti-epcam antibody and uses thereof |
| 01/13/2010 | EP2142569A2 Non-fucosylated antibodies |
| 01/13/2010 | EP2142568A1 Antibodies that bind both il-17a and il-17f and methods of using the same |
| 01/13/2010 | EP2142567A2 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| 01/13/2010 | EP2142213A2 Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof |
| 01/13/2010 | EP2142210A1 Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| 01/13/2010 | EP2142209A1 Aerosol dispersions of particles with active pharmaceutical ingredients |
| 01/13/2010 | EP2141997A1 Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| 01/13/2010 | EP1755642B1 Annexin v for preventing plaque rupture |
| 01/13/2010 | EP1701737B1 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 01/13/2010 | EP1629011B1 Human anti-human cd3 binding molecules |
| 01/13/2010 | EP1558749B1 Atypical protein kinase c isoforms in disorders of the nervous system and cancer |
| 01/13/2010 | EP1499886B1 Methods and compositions for inducing an immune response |
| 01/13/2010 | EP1427462B1 Method for inducing selectively suppressed immune response |
| 01/13/2010 | EP1394253B1 Anti-human ovarian cancer -anti-cd3 bispecific antibody |
| 01/13/2010 | EP1221968B1 Method of obtaining cellular immune responses from proteins |
| 01/13/2010 | CN101626785A Nerve elongation promoter and elongation inhibitor |
| 01/13/2010 | CN101626784A Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions |
| 01/13/2010 | CN101626783A Ephb3-specific antibody and uses thereof |
| 01/13/2010 | CN101626782A Human antibodies that bind CD22 and uses thereof |
| 01/13/2010 | CN101623498A Dual-target tumor vaccine based on tumor endothelium marker-8 gene and preparation method thereof |
| 01/13/2010 | CN101623497A Method for removing residual DNA from hydrophobia vaccine |
| 01/13/2010 | CN100580080C Corona-virus-like particles comprising functionally deleted genomes |
| 01/13/2010 | CN100579985C Streptococcus agalactiae antigens I and II |
| 01/13/2010 | CN100579581C Compositions for the treatment of mycobacterial infections |
| 01/13/2010 | CN100579580C Mucosal meningococcal vaccines |
| 01/13/2010 | CN100579579C Anti-cancer and anti-infectious disease compositions and methods for using same |
| 01/13/2010 | CN100579578C Pyloric spiral bacillus antigen recombinant vaccine |
| 01/13/2010 | CN100579577C Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 01/12/2010 | US7645743 Administering immunity linkers with more than one binding site, wherein second site binds to target and individual has pre-existing cellular or humoral immune response to first site; high speed response to public health needs such as pandemic infections; biological warfare; vaccines |
| 01/12/2010 | US7645741 IAP BIR domain binding compounds |
| 01/12/2010 | US7645592 Glycoprotein VI antibodies and methods of use thereof |
| 01/12/2010 | US7645591 Method for determining the nature of an infection |
| 01/12/2010 | US7645577 Polypeptides extracellular matrix adhesin (Ema)A, EmaB, EmaC, EmaD and EmaE |
| 01/12/2010 | US7645570 Botulinum toxin screening assays |
| 01/12/2010 | US7645456 Clonal strain of attenuated vaccinia virus that can be used to prevent or treat small pox |
| 01/12/2010 | US7645455 Chimeric lyssavirus nucleic acids and polypeptides |
| 01/12/2010 | US7645454 Prostate specific antigens and uses thereof |
| 01/12/2010 | US7645453 Detecting cancer malignancy by determining the abundance of alpha-enolase antibodies in a sample |
| 01/12/2010 | US7645452 RTVP based compositions and methods for the treatment of prostate cancer |
| 01/12/2010 | US7645451 Treating a subject at risk of a tumor characterized by aberrant Dkk-1 expression using e.g. antibody, antisense agent |
| 01/12/2010 | US7645450 For treating a hTNF- alpha -related disease such as Rheumatoid arthritis, Crohn's disease, psoriatic arthritis, psoriasis, septicemia, asthma, Wegener's granulomatosis, inflammation, and ankylosing spondylitis |
| 01/12/2010 | US7645449 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 01/12/2010 | US7645448 Prevention, therapy of pathogen infections; anchoring on surface of target cells; viricides; gene therapy; neuraminidase activity; antiallergens; antiinflammatory agents |
| 01/12/2010 | CA2438143C Modified proteins, designer toxins, and methods of making thereof |
| 01/12/2010 | CA2427467C Sn-38 lipid complexes and methods of use |
| 01/12/2010 | CA2409995C Online media exchange |
| 01/12/2010 | CA2402339C Viral antigen and vaccine against isav (infectious salmon anaemia virus) |
| 01/12/2010 | CA2331846C Expression vectors for stimulating an immune response and methods of using the same |
| 01/12/2010 | CA2309604C Compositions and methods for targeted delivery of factors |
| 01/12/2010 | CA2300360C Novel antigen constructs useful in the detection and differentiation of antibodies to hiv |
| 01/12/2010 | CA2272845C Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes |
| 01/12/2010 | CA2201781C Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component |
| 01/12/2010 | CA2170412C Modified plant viruses as vectors of heterologous peptides |
| 01/12/2010 | CA2144674C Use of azoles as virucidal agents in solutions of biologically active proteins |
| 01/07/2010 | WO2010003101A2 Il6 immunotherapeutics |
| 01/07/2010 | WO2010003085A1 Fusion proteins and their use in the diagnosis and treatment of leishmaniasis |
| 01/07/2010 | WO2010003057A2 Treating cancer |
| 01/07/2010 | WO2010003053A2 Hsv-2 peptides for stimulation of cytotoxic t lymphocytes |
| 01/07/2010 | WO2010003009A2 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| 01/07/2010 | WO2010002989A2 Vaccines comprising pasteurella multocida recombinant filamentous hemagglutinin peptides |
| 01/07/2010 | WO2010002983A2 Composition and methods for eliciting an immune response |
| 01/07/2010 | WO2010002867A2 Multivalent antihelminthic vaccine |
| 01/07/2010 | WO2010002862A2 Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
| 01/07/2010 | WO2010002822A1 Anti-gd2 antibodies and methods and uses related thereto |
| 01/07/2010 | WO2010002818A2 Malaria vaccine of self-assembling polypeptide nanoparticles |
| 01/07/2010 | WO2010002804A2 Method and compositions for inhibition of double stranded dna viruses |
| 01/07/2010 | WO2010002537A1 Cattle vaccines |
| 01/07/2010 | WO2010002418A2 Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
| 01/07/2010 | WO2010001932A1 Pharmaceutical composition containing surface-coated microparticles |
| 01/07/2010 | WO2010001908A1 Anti-cd27 antibody |
| 01/07/2010 | WO2010001671A1 Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle devive |
| 01/07/2010 | WO2010001659A1 Method for production of preparation containing single useful substance having polypeptide |
| 01/07/2010 | WO2010001617A1 Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers |
| 01/07/2010 | WO2010001585A1 Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| 01/07/2010 | WO2010001409A2 Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same |
| 01/07/2010 | WO2010000875A1 Erythropoietin receptor antibody and uses thereof |
| 01/07/2010 | WO2010000873A1 Modification of allergens for immunotherapy |
| 01/07/2010 | WO2010000849A2 A method for the screening of conserved secreted proteins |
| 01/07/2010 | WO2010000758A1 Method for optimizing proteins having the folding pattern of immunoglobulin |
| 01/07/2010 | WO2010000485A1 Msp-1 protein preparations from plasmodium |
| 01/07/2010 | WO2010000041A1 Anti- p2x7 peptides and epitopes |
| 01/07/2010 | WO2010000025A1 Anti-pamp therapeutic antibodies |
| 01/07/2010 | WO2009143524A3 Nanoemulsion vaccines |
| 01/07/2010 | WO2009140626A3 Long term disease modification using immunostimulatory oligonucleotides |
| 01/07/2010 | WO2009134952A3 Potent conjugates and hydrophilic linkers |
| 01/07/2010 | WO2009131730A3 IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
| 01/07/2010 | WO2009127666A3 Vaccination compositions or combinations against cancer |
| 01/07/2010 | WO2009126858A3 Materials and methods for improved immunoglycoproteins |
| 01/07/2010 | WO2009126805A3 Therapeutic tarageting of mmps in neutral liposomes |
| 01/07/2010 | WO2009123950A3 Chimera comprising bacterial cytotoxin and methods of using the same |
| 01/07/2010 | WO2009123894A3 Her2/neu-specific antibodies and methods of using same |
| 01/07/2010 | WO2009120903A3 Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| 01/07/2010 | WO2009120899A3 G coupled protein receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| 01/07/2010 | WO2009114207A3 Replication-defective flavivirus vaccines and vaccine vectors |
| 01/07/2010 | WO2009112502A9 Agent for treating disease |
| 01/07/2010 | WO2009111450A3 Metalloproteinase 9 binding proteins |
| 01/07/2010 | WO2009100194A3 Camptothecin-binding moiety conjugates |
| 01/07/2010 | WO2009082651A3 Attenuated uracil auxotroph of an apicomplexan and use thereof |